Peer-Reviewed Research
CJC-1295 without DAC is commonly identified as Modified GRF (1-29), a short-acting analog of growth hormone-releasing hormone. Direct peer-reviewed clinical research specifically using the commercial term “CJC-1295 without DAC” is extremely limited. Therefore, the publications below are separated into research relevant to Modified GRF (1-29), long-acting CJC-1295 with DAC, and broader reviews of GHRH analogs. The long-acting CJC-1295 studies should not be presented as direct evidence for the no-DAC form.
Original Research
Glycine-modified growth hormone secretagogues identified in seized and internet-sourced products
Journal: Drug Testing and Analysis
Published: 2019
Study Type: Analytical laboratory research
Summary
Researchers analyzed products obtained through seizures and internet sources for modified peptide growth-hormone secretagogues. Modified GRF (1-29) was among the compounds identified. This study addressed peptide identification and analytical detection rather than biological effectiveness or clinical outcomes.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/30136411/
Foundational CJC-1295 Research
Long-acting DAC form—not CJC-1295 without DAC
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
Journal: Endocrinology
Published: 2005
Study Type: Laboratory and preclinical animal research
Summary
This study evaluated modified hGRF (1-29) compounds engineered to bind circulating albumin. Researchers identified CJC-1295 as a stable, biologically active analog capable of stimulating growth-hormone secretion with an extended plasma half-life. The compound studied contained the albumin-binding modification associated with CJC-1295 with DAC and was not the no-DAC product.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/15817669/
DOI:
https://doi.org/10.1210/en.2004-1286
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Journal: The Journal of Clinical Endocrinology & Metabolism
Published: 2006
Study Type: Randomized, double-blind, placebo-controlled human clinical trials
Summary
Researchers evaluated single and repeated doses of long-acting CJC-1295 in healthy adults. Treatment produced sustained increases in circulating growth hormone and IGF-I. This clinical study evaluated the albumin-binding, long-acting DAC form and should not be described as a clinical trial of Modified GRF (1-29) or CJC-1295 without DAC.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/16352683/
DOI:
https://doi.org/10.1210/jc.2005-1536
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Journal: The Journal of Clinical Endocrinology & Metabolism
Published: 2006
Study Type: Human clinical trial
Summary
This study examined growth-hormone secretion patterns after administration of long-acting CJC-1295. Researchers found that overall growth-hormone and IGF-I concentrations increased while endogenous growth-hormone pulsatility was preserved. The compound studied was the long-acting DAC form rather than CJC-1295 without DAC.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/17018654/
DOI:
https://doi.org/10.1210/jc.2006-1702
Recent Review Articles
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Journal: International Journal of Molecular Sciences
Published: 2026
Study Type: Scientific review
Summary
This review evaluates approved and investigational peptides used in metabolic, endocrine, and aesthetic settings, including CJC-1295 and Ipamorelin. It discusses proposed biological effects, clinical evidence, safety limitations, and regulatory status. The article reviews CJC-1295 broadly and does not provide a dedicated clinical trial of the no-DAC form.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/42123471/
Read Full Text:
https://pmc.ncbi.nlm.nih.gov/articles/PMC13164565/
DOI:
https://doi.org/10.3390/ijms27093890
Injectable Peptides in Sports Medicine: A Structured Narrative Review
Published: 2026
Study Type: Structured narrative review
Summary
This review examines injectable peptides discussed in sports medicine, including CJC-1295 and related growth-hormone secretagogues. The authors distinguish mechanistic and preclinical evidence from established human clinical outcomes and emphasize the limited direct evidence supporting many investigational peptides.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/42160466/
Therapeutic Peptides in Orthopaedics: Applications, Evidence, and Future Directions
Published: 2026
Study Type: Scientific review
Summary
This review discusses investigational peptides used in orthopedic and regenerative research, including CJC-1295, Ipamorelin, Tesamorelin, and other growth-hormone–axis compounds. It summarizes proposed signaling pathways while noting that the clinical evidence for many unapproved peptides remains limited.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/41490200/
Additional CJC-1295 and Modified GRF (1-29) Publications
Browse CJC-1295 research:
https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295
Browse Modified GRF (1-29) research:
https://pubmed.ncbi.nlm.nih.gov/?term=%22modified+GRF+1-29%22
Research Disclaimer
The information presented in this Research Library is provided for educational and scientific reference purposes only and is based on published peer-reviewed research. Research findings continue to evolve, and investigational compounds may not be approved for clinical use. All Pearland Peptides products are supplied For Research Use Only and are not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease.